Sex Difference in Cognitive Impairment Associated with Diabetes-Mellitus and Beneficial Effect of Spironolactone on This Cognitive Decline

Jun Iwanami,Masaki Mogi,Kana Tsukuda,Li-Juan Min,Akiko Sakata,Fei Jing,Kousei Ohshima,Masatsugu Horiuchi

DOI: https://doi.org/10.1016/j.jalz.2011.05.1880

2011-01-01

Abstract:Diabetes mellitus has been reported to be a risk factor for dementia including Alzheimer's disease (AD). Moreover, women with diabetes mellitus exhibit severer cognitive decline compared with men. Recently, it is reported that hypertensives with potassium-sparing diuretics show a significant decrease in the onset of AD. Here, we investigated the sex difference in cognitive function using diabetes mellitus model mouse, KKAy and the effects of spironolactone on this cognitive impairment. C57BL/6J and KKAy mice were used for this study. A part of 8-week-old female KKAy mice were subjected to ovariectomy (OVX) and treated with E2. Some 8-week-old mice were treated with 50 mg/kg/day of spironolactone. Cognitive function was evaluated with passive avoidance task and the Morris water maze test. 1) Female KKAy mice exhibited a significant reduction of avoidance rate in passive avoidance task compared with male, while this sex difference was not observed in C57BL6 mice. Reduction of avoidance rate tended to be improved by ovariectomy and E2-treated OVX female showed significant increase in avoidance rate similar to male level. In the Morris water maze test, escape latency was significantly impaired in female KKAy compared with male KKAy, while sex difference was not also observed in C57BL6 mice. This impairment was not altered significantly by OVX and E2 treatment. 2) In KKAy mice, treatment with spironolactone in female improved avoidance rate up to male level, but did not change the avoidance rate in male. In the Morris water maze, spironolactone improved escape latency in both male and female KKAy mice. Treatment with spironolactone in OVX mice also increased avoidance rate compared with non-treated-OVX mice. However, co-treatment with E2 in OVX mice failed to increase avoidance rate by spironolactone treatment. Moreover, treatment with spironolactone significantly improved escape latency in OVX mice compared with non-treated-OVX mice; however, this improvement was canceled by co-administration of E2. These results suggest that diabetic female mice exhibits severe cognitive impairment compared with diabetic male mice. Treatment with spironolactone improves diabetes mellitus-induced cognitive decline especially in female.